Skip to content
10-Q

Quarterly Report

Coherus Oncology, Inc. CHRS

0001558370-25-010803

← back to feed
Filed
Aug 7, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Jul 31, 2025 116.23M sh
Shares Diluted Q2 2025 · Jun 30, 2025 116.08M sh
Shares Diluted Q2 2025 · Jun 30, 2025 115.97M sh
Shares Diluted Q2 2025 · Jun 30, 2024 114.82M sh
Shares Diluted restated Q2 2025 · Jun 30, 2024 113.78M sh
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$72.46M
Operating Cash Flow Q2 2025 · Jun 30, 2024 $12.97M
Cash And Equivalents Q2 2025 · Jun 30, 2025 $216.89M
Cash And Equivalents Q2 2025 · Dec 31, 2024 $125.99M
Stockholders Equity Q2 2025 · Jun 30, 2025 $119.83M
Stockholders Equity Q2 2025 · Mar 31, 2025 −$183.47M
Stockholders Equity Q2 2025 · Dec 31, 2024 −$131.99M
Stockholders Equity Q2 2025 · Jun 30, 2024 −$84.11M
Stockholders Equity Q2 2025 · Mar 31, 2024 −$81.84M
Stockholders Equity Q2 2025 · Dec 31, 2023 −$193.43M
Current Liabilities Q2 2025 · Jun 30, 2025 $263.63M
Current Liabilities Q2 2025 · Dec 31, 2024 $282.98M
Total Liabilities Q2 2025 · Jun 30, 2025 $319.64M
Total Liabilities Q2 2025 · Dec 31, 2024 $580.52M
Current Assets Q2 2025 · Jun 30, 2025 $380.21M
Current Assets Q2 2025 · Dec 31, 2024 $341.58M
Total Assets Q2 2025 · Jun 30, 2025 $439.46M
Total Assets Q2 2025 · Dec 31, 2024 $448.53M
Eps Diluted Q2 2025 · Jun 30, 2025 $2.57
Eps Diluted Q2 2025 · Jun 30, 2025 $2.08
Eps Diluted Q2 2025 · Jun 30, 2024 −$0.11
Eps Diluted restated Q2 2025 · Jun 30, 2024 $0.79
Eps Basic Q2 2025 · Jun 30, 2025 $2.57
Eps Basic Q2 2025 · Jun 30, 2025 $2.08
Eps Basic Q2 2025 · Jun 30, 2024 −$0.11
Eps Basic Q2 2025 · Jun 30, 2024 $0.79
Sga Expense Q2 2025 · Jun 30, 2025 $26.04M
Sga Expense Q2 2025 · Jun 30, 2025 $52.06M
Sga Expense restated Q2 2025 · Jun 30, 2024 $27.52M
Sga Expense restated Q2 2025 · Jun 30, 2024 $67.75M
Rd Expense Q2 2025 · Jun 30, 2025 $26.31M
Rd Expense Q2 2025 · Jun 30, 2025 $50.66M
Rd Expense restated Q2 2025 · Jun 30, 2024 $20.6M
Rd Expense restated Q2 2025 · Jun 30, 2024 $49.02M
Net Income Q2 2025 · Jun 30, 2025 $297.77M
Net Income Q2 2025 · Jun 30, 2025 $241.2M
Net Income Q2 2025 · Mar 31, 2025 −$56.57M
Net Income Q2 2025 · Jun 30, 2024 −$12.92M
Net Income Q2 2025 · Jun 30, 2024 $89.95M
Net Income Q2 2025 · Mar 31, 2024 $102.88M
Operating Income Q2 2025 · Jun 30, 2025 −$45.49M
Operating Income Q2 2025 · Jun 30, 2025 −$90.92M
Operating Income restated Q2 2025 · Jun 30, 2024 −$39.63M
Operating Income restated Q2 2025 · Jun 30, 2024 −$107.41M
Cost Of Revenue Q2 2025 · Jun 30, 2025 $3.4M
Cost Of Revenue Q2 2025 · Jun 30, 2025 $6.05M
Cost Of Revenue restated Q2 2025 · Jun 30, 2024 $1.81M
Cost Of Revenue restated Q2 2025 · Jun 30, 2024 $3.25M